For Immediate Release
Chicago, IL - January 4, 2012 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Walgreens ( WAG ), Express Scripts ( ESRX ), Medco Health Solutions ( MHS ), Supervalu ( SVU ) and CVS Caremark ( CVS ).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Tuesday's Analyst Blog:
Walgreens Plans to Offset Express Scripts Loss
Walgreens ( WAG ) is commencing the New Year with efforts aimed at minimizing the impact of the non-renewal of the Express Scripts ( ESRX ) contract, which has just lapsed. With the intention of retaining Express Scripts' clients, Walgreens recently came up with its comprehensive Patient Transition Plan, which will help smooth the transition of existing members of the Express Scripts pharmacy network to another community pharmacy. Under this plan, Walgreens is providing several discounts to the members of Walgreens Prescriptions Savings Club, which facilitates savings on over 8,000 brand names and all generic drugs.
The six-month dispute regarding the Express Scripts contract took its toll on Walgreens' first quarter 2012 results. The company's bottom-line was impacted by 2 cents per share from the loss of pharmacy sales and expenses associated with the dispute. With the termination of the Express Scripts contract, effective January 1, 2012, Walgreens' 7,800 pharmacies are no longer a part of Express Scripts' pharmacy provider network.
The contract accounted for $5.3 billion of sales in fiscal 2011 as Express Scripts processed 88 million prescriptions filled by Walgreens. In the recently concluded quarter, the pharmacy benefit manager processed as many as 26 million prescriptions from Walgreens.
However, Walgreens is expanding its business with other payers and customers and implementing cost-control initiatives. The company is reassured by the fact that more than 100 of Express Scripts clients, encompassing health plans and employers, would continue with Walgreen pharmacies in 2012. The company aims to retain 10 million prescriptions annually and maintain 97-99% of the 2011 prescription volumes at fiscal 2012 end. This guidance takes into account the loss of major Express Scripts clients such as the Department of Defense Tricare plan.
Considering that almost 75% of the business from Express Scripts' clients would be lost, Walgreens expects to offset 50% of the gross profit reduction in fiscal 2012 by leveraging selling, general and administrative expenses and cost of goods sold. However, the majority of these cost cuts are expected to take effect from the latter half of fiscal 2012. Additional reimbursement pressure may crop up for Walgreens if the proposed merger between Express Scripts and Medco Health Solutions ( MHS ) takes place.
Amidst a fiercely competitive landscape, major retailers are also trying their best to lure Express Scripts patients who would otherwise lose access to Walgreens pharmacies beginning 2012. Jewel-Osco, a Supervalu ( SVU ) company, is trying to get hold of Walgreens customers with their 173 operational stores and is also planning to hire additional manpower to cater to these new patients. Besides, CVS Caremark ( CVS ) with its 7,304 retail drugstores is also in the race.
Despite the competitive scenario, we are optimistic about Walgreens' long-term prospects. The introduction of new generic drugs should help improve the company's gross margins in the second half of fiscal 2012. Moreover, a strong cash balance enables the company to reward its shareholders. During the last reported quarter, the company enhanced shareholders' value through dividend payments and share repurchases amounting to $803 million ($601 million in share repurchases and $202 million in dividends). In the last eight years, the company's dividend has grown at a compound annual growth rate ("CAGR") of nearly 22%.
Currently, we are Neutral on Walgreens, which corresponds to the Zacks #3 Rank (short-term Hold rating).
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515 .
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518 .
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research